Latest / Stock Movers / Intuit Slumps, Spyre Therapeutics Mixed, Dick's Sporting Goods Slides
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios. Podcasts. Radio. News. The Stock Movers Report.
- 0:10Speaker 1: Your roundup of companies making moves in the stock market.
- 0:13Speaker 1: Harnessing the power of Bloomberg data.
- 0:16Speaker 2: I'm Tim Stenevek along with Nora Melinda. Let's take a
- 0:20Speaker 2: look at some stocks on the move today. We're joined
- 0:21Speaker 2: by Bloomberg News Activities Reporter Avalon Purnell. Hey, Avalon.
- 0:25Speaker 3: Hi.
- 0:25Speaker 4: We have to start off with probably the biggest story
- 0:27Speaker 4: in post-market. That's Intuit. That's ticker I-N-T-U. currently slumping about 9.3% post-market.
- 0:34Speaker 4: And that's after the tech software maker behind names like
- 0:36Speaker 4: QuickBooks and TurboTax. gave an annual profit forecast that fell
- 0:40Speaker 4: pretty well short of expectations. Vital Knowledge highlighting that this
- 0:45Speaker 4: is just generally an underwhelming release, and noting as well
- 0:48Speaker 4: that while the guidance definitely undershot consensus, the company's performance
- 0:52Speaker 4: isn't nearly as bad as headlines may seem. Also worth noting, though,
- 0:56Speaker 4: that despite this, the print is definitely going to add
- 0:58Speaker 4: fuel to investor concerns about the so-called SaaSpocalypse. And, you know,
- 1:03Speaker 4: adding to the questions about how exactly is AI going
- 1:06Speaker 4: to cannibalize or change the business of software as a
- 1:09Speaker 4: service companies?
- 1:10Speaker 2: Yeah, this stock was getting hammered this year, has been
- 1:12Speaker 2: getting hammered this year, down more than 40% going into
- 1:15Speaker 2: today's print. So this isn't helping. Look, it's post-market right now.
- 1:18Speaker 2: We got to wait to see what exactly happens on
- 1:20Speaker 2: the call and what the trade looks like tomorrow. But
- 1:22Speaker 2: as of now, not looking too promising.
- 1:24Speaker 4: Exactly.
- 1:25Speaker 3: Interesting, interesting. Spire?
- 1:27Speaker 4: Spire? Therapeutics, is that how you?
- 1:29Speaker 3: Yes, yes.
- 1:30Speaker 2: You can always count on a healthcare name.
- 1:31Speaker 3: Oh, yeah.
- 1:32Speaker 1: Of course.
- 1:32Speaker 4: That is ticker S-Y-R-E. It's currently also falling about 13% post-market.
- 1:38Speaker 4: And that's after the biotech reported some mixed early stage
- 1:41Speaker 4: results for its drug to treat patients with rheumatoid arthritis.
- 1:44Speaker 4: Perhaps more importantly, the drug kind of fell short of
- 1:47Speaker 4: the company's internal bar for developing it as a monotherapy.
- 1:51Speaker 4: That's really important considering the fact that immunology and also
- 1:54Speaker 4: inflammation is just a red hot area within therapeutics. We
- 1:57Speaker 4: had Humira, which was a blockbuster drug, and people are
- 2:00Speaker 4: just trying to crowd into that area. But Stiefel actually
- 2:03Speaker 4: writing already that they expect to see weakness given how
- 2:06Speaker 4: underwhelming that data was.
- 2:07Speaker 3: Hold on.
- 2:07Speaker 2: Can I ask you some more details about this just
- 2:09Speaker 2: from a health perspective? When you talk about these anti-inflammatories,
- 2:13Speaker 2: what are they treating?
- 2:14Speaker 4: Well, they're treating a wide range of autoimmune diseases. So
- 2:17Speaker 4: you have things like rheumatoid arthritis, but also other things
- 2:20Speaker 4: that could be autoimmune related.
- 2:22Speaker 2: So it's all autoimmune?
- 2:23Speaker 4: Generally speaking, yes.
- 2:24Speaker 2: And there has been a lot written about a rise
- 2:26Speaker 2: in autoimmune conditions among adults these days.
- 2:29Speaker 3: Yes.
- 2:30Speaker 4: Exactly. Plus, I mean, this is also an area where
- 2:32Speaker 4: you could potentially have more biologics, which those are protected differently,
- 2:36Speaker 4: meaning with like your patent exclusivity, you're going to be
- 2:38Speaker 4: able to have a much longer time before generics can
- 2:41Speaker 4: come in, which is another really important piece when you're
- 2:43Speaker 4: looking at what could be a very profitable area of
- 2:46Speaker 4: the markets you likely would want to go towards there.
- 2:49Speaker 2: A couple post-market movers. We can't forget about a huge
- 2:52Speaker 2: mover in today's cash session.
- 2:55Speaker 1: Yes.
- 2:56Speaker 4: Another loser on the market, unfortunately, is Dick's Sporting Goods.
- 2:59Speaker 4: That's tickered DKS. It dropped by a record 31% into
- 3:03Speaker 4: the close today. And that's after the retailer slashed its
- 3:06Speaker 4: annual net sales and adjusted operating income. Guidance amid weakness
- 3:10Speaker 4: at Foot Locker. Their chairman also saying in the earnings
- 3:13Speaker 4: call that they're expecting more pain to come, especially in
- 3:17Speaker 4: a very key area of sneakers. And I mean, that
- 3:20Speaker 4: also led a lot of different athletic companies to also
- 3:23Speaker 4: drop as well. Looking at Nike, Lululemon, Deckers, all lower
- 3:27Speaker 4: in today's session, just given this earnings print.
- 3:30Speaker 3: Yeah, I mean, Nike is supplier to both Dick's Sporting
- 3:32Speaker 3: Goods and Foot Locker. Take a look at Dick's and Nike.
- 3:36Speaker 3: And they're actually both down still here as we take
- 3:39Speaker 3: a look at, of course, how it ended on the day.
- 3:41Speaker 3: But it looks like they're a little bit higher in
- 3:42Speaker 3: the post-market trade. So we'll see if this settles by tomorrow.
- 3:47Speaker 1: The Stock Movers Report from Bloomberg Radio. Check back with
- 3:51Speaker 1: us throughout the day for the latest roundup of companies
- 3:53Speaker 1: making news on Wall Street. And for the latest market-moving headlines,
- 3:58Speaker 1: listen to Bloomberg Radio Live. Catch us on YouTube, Bloomberg.com,
- 4:02Speaker 1: and on Apple CarPlay and Android Auto with the Bloomberg
- 4:05Speaker 1: Business app.